Bryony Hicks

Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial.

E. Anderson, Lee-Jah Chang, Aseem Pandey, 2021, Vaccine.

Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine.

S. Gurunathan, M. Bologa, R. Hopfer, 2012, Vaccine.

Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae.

D. Briles, P. Lau, M. Ochs, 2008, Microbial pathogenesis.